Citi: Raises CSPC PHARMA (01093) target price to HK$15, maintains "Buy" rating.
Citi believes that CSPC PHARMA's recovery in core drug sales, improved cost efficiency, and the increasing normalization of business development milestone revenue are conducive to earnings visibility.
Citi issued a research report stating that CSPC PHARMA (01093)'s third-quarter results beat expectations, benefiting from licensing revenue and core business recovery. The bank raised its target price from HK$14.6 to HK$15 and maintained its "Buy" rating.
The bank believes that the recovery in core drug sales, improved cost efficiency, and the increasing normalization of business development milestone revenue are conducive to earnings visibility. Revenue from the central nervous system (CNS) business grew 29.1% year-on-year in the first nine months, accounting for approximately 48% of finished drug sales excluding licensing. Management expects more than 10 new products and indications to be launched next year, supporting overall positive growth.
The bank raised its 2026 revenue forecast by 2% and its 2026 net profit forecast by 3% on higher margin assumptions, while slightly adjusting its 2027 and 2028 forecasts.
Related Articles

MS CONCEPT (08447) announces interim results, with a net loss of HK$1.521 million.

Zijin Mining Group (02899) plans to repurchase RMB2 billion to RMB3 billion of its A-shares.

US Stock Market Move | NVIDIA Corporation (NVDA.US) rose 4%; institutions believe the stock price has already priced in the risk of leadership changes.
MS CONCEPT (08447) announces interim results, with a net loss of HK$1.521 million.

Zijin Mining Group (02899) plans to repurchase RMB2 billion to RMB3 billion of its A-shares.

US Stock Market Move | NVIDIA Corporation (NVDA.US) rose 4%; institutions believe the stock price has already priced in the risk of leadership changes.






